Fibrin(ogen) in Abdominal Aortic Aneurysm Pathogenesis

Information

  • Research Project
  • 10244953
  • ApplicationId
    10244953
  • Core Project Number
    F31HL143987
  • Full Project Number
    5F31HL143987-04
  • Serial Number
    143987
  • FOA Number
    PA-16-308
  • Sub Project Id
  • Project Start Date
    9/1/2018 - 5 years ago
  • Project End Date
    8/31/2022 - a year ago
  • Program Officer Name
    MEADOWS, TAWANNA
  • Budget Start Date
    9/1/2021 - 2 years ago
  • Budget End Date
    8/31/2022 - a year ago
  • Fiscal Year
    2021
  • Support Year
    04
  • Suffix
  • Award Notice Date
    8/18/2021 - 2 years ago

Fibrin(ogen) in Abdominal Aortic Aneurysm Pathogenesis

PROJECT SUMMARY/ABSTRACT Abdominal Aortic Aneurysm (AAA) results in significant morbidity and mortality in upwards to 15,000 patients in the United States. No effective pharmaceutical intervention exists and treatment is limited to surgical intervention at the point of maximal expansion. The pathogenesis of this disease is poorly understood, making development of pharmaceutical intervention difficult. The protein fibrinogen, an important participant in hemostatic, inflammatory and wound-healing processes, is known to be elevated in AAA patients. However, this observation has not been adequately investigated, and no mechanism to explain this elevation has been experimentally identified. Work performed in our lab has demonstrated that depletion of fibrinogen in a mouse model successfully attenuates an accepted animal model of AAA, and decreases inflammatory cytokines. However, the molecular mechanism(s) responsible for fibrinogen mediated AAA pathogenesis remains unclear. As such, understanding the molecular mechanism(s) responsible for fibrinogen depletion attenuating AAA could lead to novel therapeutic strategies in AAA. The primary goal of this proposal is investigate the mechanisms by which fibrinogen contributes to AAA pathogenesis. Specifically, we will study how macrophage binding with fibrinogen contributes to AAA pathogenesis, and how fibrin clot structure and accompanying fibrinolytic resistance contributes to AAA pathogenesis. We hypothesize that fibrinogen deposition into AAA accelerates aneurysmal growth by increasing the activation of coagulation and inflammation. This hypothesis will be addressed with two specific aims and several unique mouse models. In these aims, we will assess the influence of fibrinogen on AAA through hemostatic action via analysis of fibrin clot structure and factor XIII (FXIII; aim 1) and inflammatory action via deletion of the macrophage binding site in the fibrinogen gamma chain (aim 2). The long term objective of this work is to identify a role for fibrinogen in this disease process. If successfully completed, identified a mechanism to explain fibrinogen elevation in AAA patients. The outcomes from the proposed studies are expected to have also significantly advanced our current knowledge of AAA pathogenesis, and have a positive impact on our ability to identify possible targets for AAA therapy. This fellowship grant will also train the principle investigator in molecular biology and functional genomics in order to establish a research career in the field.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    F31
  • Administering IC
    HL
  • Application Type
    5
  • Direct Cost Amount
    38717
  • Indirect Cost Amount
  • Total Cost
    38717
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    837
  • Ed Inst. Type
    SCHOOLS OF MEDICINE
  • Funding ICs
    NHLBI:38717\
  • Funding Mechanism
    TRAINING, INDIVIDUAL
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    UNIVERSITY OF CINCINNATI
  • Organization Department
    PATHOLOGY
  • Organization DUNS
    041064767
  • Organization City
    CINCINNATI
  • Organization State
    OH
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    452210001
  • Organization District
    UNITED STATES